Antithrombotic Drugs: World Industry and Market Prospects 2014-2024

Description

Antithrombotic Drugs: World Industry andAntithrombotic Drugs: World Industry and Market Prospects 2014-2024 PR Newswire LONDON, February 28, 2014 Treating thrombosis - new analysis showing trends, R&D, and revenue forecasts See the future of antithrombotic medicines. For those treatments you can get new sales predictions, also exploring research and development. Discover business potentials. And you assess results, trends, technologies, therapies, and opportunities. Visiongain's report forecasts those revenues to 2024 at overall world market, submarket, product, and national level. You stay ahead in data on treating thrombotic disorders, finding commercial prospects to benefit your influence. Read on, then, to explore those drug sales and find what they could be worth in future. Forecasts to 2024 and other analyses predict and explain the antithrombotics market Why miss data you need? Why struggle to find it? Instead our report gives you revenue forecasts to 2024, also with recent results, growth rates, market shares, and discussions. Also you find the potential of research and development. The study also gives 82 tables, 70 charts, and interviews with four authorities in that field. There you assess the future for treatments to prevent blood clotting or to dissolve blood clots. The following sections explain what the new investigation gives. Forecasting of that world market and its segments - what's likely to happen? What're the secrets of that industry's progress?

Informations

• Publié par: visiongain
• Publié le: 28 février 2014
• Nombre de lectures: 25
• Langue: English

Extrait

Antithrombotic Drugs: World Industry and Market Prospects 2014-2024

PR Newswire

LONDON, February 28, 2014

Treating thrombosis - new analysis showing trends, R&D, and revenue forecasts

See the future of antithrombotic medicines. For those treatments you can get new sales predictions, also exploring research and development. Discover business potentials. And you assess results, trends, technologies, therapies, and opportunities.

Visiongain's report forecasts those revenues to 2024 at overall world market, submarket, product, and national level. You stay ahead in data on treating thrombotic disorders, finding commercial prospects to benefit your influence.

Read on, then, to explore those drug sales and find what they could be worth in future.

Forecasts to 2024 and other analyses predict and explain the antithrombotics market

Why miss data you need? Why struggle to find it? Instead our report gives you revenue forecasts to 2024, also with recent results, growth rates, market shares, and discussions.

Also you find the potential of research and development. The study also gives 82 tables, 70 charts, and interviews with four authorities in that field.

There you assess the future for treatments to prevent blood clotting or to dissolve blood clots. The following sections explain what the new investigation gives.

Forecasting of that world market and its segments - what's likely to happen?

What're the secrets of that industry's progress? Discover in our report overall world revenue to 2024 for antithrombotic medicines.

Also find individual revenue predictions to 2024 for eight therapeutic submarkets at world level:
• Antiplatelet agents
• Anticoagulants
• Fibrinolytic treatments.

And get forecasts for these anticoagulant drug classes:
• Heparins
• Direct thrombin inhibitors
• Direct factor Xa inhibitors
• Vitamin K antagonists
• Other therapeutics.

There you assess outlooks for sales expansion, hearing where you could profit. So investigate competition and rising sales. And see the lucrative possibilities there.

And you also find top products' potentials.

To see an exec summary of this report please email Sara Peerun on [e-mail]

Predictions of leading products' sales

How will individual drugs perform to 2024 at world level? Our study forecasts revenues of 15 brands. Assess products including these:
• Plavix
• Lovenox
• Pradaxa
• Xarelto
• Activase
• Effient.

There you find drugs and years with highest predicted sales. Also you examine competitors. You see what's happening, understanding challenges, trends, competition and opportunities.

That work also shows geographical revenue predictions.

National markets - what outlooks for revenues?

In developed and developing countries, many opportunities for producers and sellers of those medicines will occur from 2014 to 2024. See where and how.

Our analyses show you individual revenue forecasts to 2024 for 11 national markets:
• United States (US)
• Japan
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
• BRIC nations - Brazil, Russia, India, and China.

There you explore progress, needs and opportunities. What events change that market? Our work shows you, discussing trends and needs.

Events affecting developers, producers, and sellers

The report also explains issues, forces, and events affecting the antithrombotics industry and market from 2014, including these:
• Opportunities for novel therapies, including biological drugs (biologics) and warfarin replacements
• Pulmonary embolism, stroke prevention and acute coronary syndrome (ACS) - needs for thrombotic disease management
• Generic competition and development of existing drugs
• Guidelines for approval of biosimilar low molecular weight heparins (LMWHs)
• Demand for antidotes to novel oral anticoagulants
• Vitamin K antagonist and direct factor Xa inhibitor R&D pipelines.

You find, then, what stimulates and restrains players in that sector, and affects its results.

To see an exec summary of this report please email Sara Peerun on [e-mail]

Analysis of companies and potential for market growth - what revenues are possible?

What happens next? From 2014, new treatments and demands from patients, doctors, and payers encourage investments, medical advances, and higher revenues from that applied haematology. Our study predicts that world market will reach $20.4bn in 2018.

You also see what organisations hold most potential. Examine companies, including these:
• Sanofi
• Bristol-Myers Squibb
• Boehringer Ingelheim
• Bayer
• Johnson & Johnson.

And also these firms:
• The Medicines Company
• Genentech
• Otsuka
• Eli Lilly
• Sandoz.

You find 100 organisations mentioned. You also get four interviews with other authorities in that field, helping you stay ahead.

Ways Antithrombotic Drugs: World Industry and Market Prospects 2014-2024  helps

In particular, our new investigation gives you this knowledge:
• Revenues there to 2024 at world level, for 8 submarkets, and 15 products - assess outlooks for production, marketing, and sales
• Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia - investigate developed and developing countries for potential revenues
• Prospects for established competitors, rising companies, and new entrants - explore portfolios, results, strategies, R&D, and outlooks for success.

Information found nowhere else, helping your searches, analyses, and plans

Our study gives independent analysis. There you receive competitive intelligence found only in our work, finding where progress and money lie. You explore the commercial possibilities.

So with our data you're less likely to fall behind in knowledge or miss opportunity. Being free to choose, you find with our report how you could save time and effort. And also help your planning, decisions, authority, and competing.

Our new report is for everyone analysing medications for thrombosis treatment and prevention. There you discover trends, discussions and sales predictions. Avoid missing out - please order now.

To see an exec summary of this report please email Sara Peerun on [e-mail]

Companies Listed in this report:
Abbott Laboratories
Ablynx
Aché
AdvanceCor
Alchemia
Amneal Pharms
Amphastar Pharmaceuticals
App Pharmaceuticals
ARCA Biopharma
Armetheon
ARYx Therapeutics
Asahi Kasei Pharma America
Aspen
Astellas Pharma
AstraZeneca
Barr Laboratories
Bayer
Baylor College of Medicine, Houston, Texas
Bharat Biotech
BioVascular
Boehringer Ingelheim
Bristol-Myers Squibb
Canyon Pharmaceuticals
Committee on Medicinal Products for Human Use (CHMP)
CSL Behring
Daiichi Sankyo
Dexa Medica Group
Diakron Pharmaceuticals
Dr. Reddy's Laboratories
DuPont Merck
Eisai
Eli Lilly
EMS
Endo Laboratories
ESP Pharma
Eurofarma
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Fournier Pharma
Gate Pharmaceuticals
Genentech
German Institute for Quality and Efficiency in Health Care (IQWiG)
GlaxoSmithKline (GSK)
Grifols Therapeutics
Hoechst Marion Roussell
Hospira
Hypermarcas
Indonesia University
Invagen Pharms
IPCA Labs
Isis Pharmaceuticals
Johns Hopkins Medicine
Johnson & Johnson (J&J)
Kowa
Kyowa Hakko
Lee's Pharmaceutical
LG Life Sciences
LIMES Institute
Lundbeck
Merck & Co.
Mitsubishi
Mitsubishi Tanabe Pharma
Momenta Pharmaceuticals
Mylan Pharmaceuticals
National Health Service (NHS)
National Institute for Health and Care Excellence (NICE)
Novartis
Nuvelo
Organon
Otsuka Pharmaceutical Company
Pfizer
Pharmaceutical and Medical Devices Agency (PMDA)
Pharmacia
PLIVA
PLx Pharma
Portola Pharmaceuticals
Pozen
Regado Biosciences
Roche
Sandoz
Sanofi
Sun Pharmaceuticals
Takeda
Taro
Teva Pharmaceuticals
The Medicines Company
ThromboGenics
Tianjin Medical
Tufts Medical Center
Unified Health System (SUS)
Universidade Federal de São Paulo
University General Hospital
University of Insubria (Italy)
Upjohn AB
US Department of Justice
USL Pharma
Virginia Commonwealth University
World Health Organization (WHO)
Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York
Zydus Cadila

To request an exec summary of this report please email Sara Peerun at [e-mail] or call Tel: [phone]

Or click on http://www.visiongain.com/Report/1208/Antithrombotic-Drugs-World-Industry-and-Market-Prospects-2014-2024